Trinity Biotech PLC (TRIB)
1.802
+0.12
(+7.27%)
USD |
NASDAQ |
May 03, 16:00
1.76
-0.04
(-2.34%)
After-Hours: 20:00
Trinity Biotech Research and Development Expense (Quarterly): 1.117M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.117M |
| September 30, 2023 | 1.169M |
| June 30, 2023 | 1.233M |
| March 31, 2023 | 0.86M |
| December 31, 2022 | 1.166M |
| September 30, 2022 | 1.023M |
| June 30, 2022 | 0.984M |
| March 31, 2022 | 0.965M |
| December 31, 2021 | 0.941M |
| September 30, 2021 | 1.063M |
| June 30, 2021 | 1.056M |
| March 31, 2021 | 1.437M |
| December 31, 2020 | 1.284M |
| September 30, 2020 | 1.265M |
| June 30, 2020 | 1.153M |
| March 31, 2020 | 1.378M |
| December 31, 2019 | 1.331M |
| September 30, 2019 | 1.233M |
| June 30, 2019 | 1.449M |
| March 31, 2019 | 1.311M |
| December 31, 2018 | 1.386M |
| September 30, 2018 | 1.292M |
| June 30, 2018 | 1.419M |
| March 31, 2018 | 1.272M |
| December 31, 2017 | 1.538M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.469M |
| June 30, 2017 | 1.322M |
| March 31, 2017 | 1.328M |
| December 31, 2016 | 1.33M |
| September 30, 2016 | 1.296M |
| June 30, 2016 | 1.267M |
| March 31, 2016 | 1.147M |
| December 31, 2015 | 1.508M |
| September 30, 2015 | 1.293M |
| June 30, 2015 | 1.269M |
| March 31, 2015 | 0.998M |
| December 31, 2014 | 0.962M |
| September 30, 2014 | 1.138M |
| June 30, 2014 | 1.155M |
| March 31, 2014 | 1.037M |
| December 31, 2013 | 1.036M |
| September 30, 2013 | 0.876M |
| June 30, 2013 | 0.924M |
| March 31, 2013 | 0.855M |
| December 31, 2012 | 0.765M |
| September 30, 2012 | 0.767M |
| June 30, 2012 | 0.753M |
| March 31, 2012 | 0.845M |
| December 31, 2011 | 0.862M |
| September 30, 2011 | 0.857M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.86M
Minimum
Mar 2023
1.449M
Maximum
Jun 2019
1.164M
Average
1.166M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Avadel Pharmaceuticals PLC | 2.359M |
| Amarin Corp PLC | 5.791M |
| DBV Technologies SA | 12.78M |
| Adaptimmune Therapeutics PLC | 33.21M |
| Akari Therapeutics PLC | -- |